An early phase II trial with L-deprenyl for the treatment of neuroleptic-induced parkinsonism

Pharmacopsychiatria. 1983 Sep;16(5):143-6. doi: 10.1055/s-2007-1019488.

Abstract

The effect of L-deprenyl on neuroleptic-induced parkinsonism was evaluated in eleven patients. No significant improvement was observed during the treatment with L-deprenyl in the overall assessment. Four patients, however, were considered responders as their total scores on the modified version of Neurological Rating Scale decreased by at least 50%. No somatic or mental complications were observed during the study. The pretreatment platelet monoamine oxidase activity of the responders was slightly but not significantly higher than that of the non-responders. The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl.

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects*
  • Antipsychotic Agents / therapeutic use
  • Drug Evaluation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Monoamine Oxidase / blood
  • Parkinson Disease, Secondary / chemically induced*
  • Parkinson Disease, Secondary / drug therapy
  • Parkinson Disease, Secondary / enzymology
  • Phenethylamines / therapeutic use*
  • Prolactin / blood
  • Schizophrenia / drug therapy*
  • Selegiline / therapeutic use*

Substances

  • Antipsychotic Agents
  • Phenethylamines
  • Selegiline
  • Prolactin
  • Monoamine Oxidase